Pangaea is currently assisting Biotech and Pharmaceutical clients to benchmark MSL Activity in Canada through their participation in a MSL Benchmarking study.

McKesson Canada presented their acquisition offer during a special assembly with the pharmacists/ shareholders of Uniprix in early May. 2017.

As part of the 2018 budget unveiled last Thursday, Ontario announced it’s new "OHIP+: Children and Youth Pharmacare" plan, a publicly funded drug coverage program for youth up to the age of 24.

The legal dispute between the Health Minister and the AQPP has found a resolution with a new agreement.

To be held Wednesday May 24th at the Canadian Consulate in Boston.

Health Canada has released a white paper outlining its proposed initiative to make specified clinical information from drug submissions and medical device applications publicly available following the completion of its regulatory review process.

Depending on how one approaches the questions posed by this article’s title, the answers are either crystal clear or clear as mud. And here’s why.

McKesson Canada announced its intent to acquire GMD PharmaSolutions (GMD), enhancing their specialty health services to patients, providers, payers and manufacturers.

Health Canada has released its revised guidelines for submission requirements for biosimilar biologic drugs. The “Guidance Document Information and Submission Requirements for Biosimilar Biologic Drugs” was posted online December 2nd 2016.

Following the special consultations on Bill 92 (An Act to extend the powers of the Régie de l’assurance maladie du Québec and to amend various legislative provisions) held last May, the Quebec Health Minister has introduced amendments to be discussed at the committee stage.